GNPX Share Price | Genprex, Inc. Stock Analysis & Recommendation

Q: How big is Genprex, Inc.?

Market Cap: As of Jun 18, Genprex, Inc. has a market capitalization of 8.70 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Genprex, Inc. reported net sales of 0.00 million and a net profit of -19.11 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1.62 million and total assets of 4.12 million.

Q: What does Genprex, Inc. do?

Overview: Genprex, Inc. is a clinical-stage gene therapy company focused on developing cancer therapies and is categorized within the Pharmaceuticals & Biotechnology industry, with a market cap of USD 8.70 Million.Financial Snapshot: Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 8.70 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.90 Return on Equity: -493.99% Price to Book: 2.25Contact Details: Address: 1601 Trinity St Bldg B, AUSTIN TX: 78712-1765 Tel: 1 512 5377997 Website: https://www.genprex.com/

Q: Is Genprex, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Genprex, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI is bearish on the weekly and shows no signal on the monthly. Bollinger Bands indicate a bearish stance on both time frames, and moving averages are mildly bearish on the daily. KST is mildly bullish on both weekly and monthly, while the Dow Theory shows no trend weekly and bearish monthly. OBV is bullish monthly but shows no trend weekly. In terms of performance, Genprex has underperformed the S&P 500 across multiple periods, with a year-to-date return of -71.29% compared to the S&P 500's 12.22%, and a one-year return of -33.01% versus 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

80.86 k

Shareholding (Sep 2025)

FII

0.04%

Held by 6 FIIs

DII

94.17%

Held by 6 DIIs

Promoter

0.00%

How big is Genprex, Inc.?

22-Jun-2025

As of Jun 18, Genprex, Inc. has a market capitalization of 8.70 million, with net sales of 0.00 million and a net profit of -19.11 million over the last four quarters. The company reported shareholder's funds of 1.62 million and total assets of 4.12 million as of Dec 24.

View full answer

What does Genprex, Inc. do?

22-Jun-2025

Genprex, Inc. is a clinical-stage gene therapy company focused on developing cancer therapies, with a market cap of USD 8.70 million and recent net profits of -4 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.

View full answer

Who are in the management team of Genprex, Inc.?

22-Jun-2025

As of March 2022, the management team of Genprex, Inc. includes J. Rodney Varner as Chairman, President, CEO, and Secretary, along with independent directors Brent Longnecker, Jose Moreno Toscano, and William Wilson.

View full answer

Is Genprex, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Genprex, Inc. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 significantly, with a year-to-date return of -71.29% compared to the S&P's 12.22%.

View full answer

Compare Genprex, Inc. with Similar Stocks

Context Therapeutics, Inc.KALA BIO, Inc.Indaptus Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.10

Return on Equity

-1,676.92%

Price to Book

6.56

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-53.09%

6 Months

-80.0%

1 Year

-91.2%

2 Years

-99.27%

3 Years

-99.94%

4 Years

-99.95%

5 Years

-99.98%

Genprex, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-3.72%

EBIT to Interest (avg)

-22.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.90

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

21.37%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.07

EV to EBIT

-0.24

EV to EBITDA

-0.24

EV to Capital Employed

4.53

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1914.67%

ROE (Latest)

-493.99%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (5.79%)

Foreign Institutions

Held by 6 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 27.69% vs 18.75% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.70",
          "val2": "-6.50",
          "chgp": "27.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.70",
          "val2": "-6.50",
          "chgp": "27.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 31.72% vs -30.38% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.20",
          "val2": "-31.10",
          "chgp": "31.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.10",
          "val2": "-30.90",
          "chgp": "31.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.70

-6.50

27.69%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-4.70

-6.50

27.69%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 27.69% vs 18.75% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-21.20

-31.10

31.83%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-21.10

-30.90

31.72%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 31.72% vs -30.38% in Dec 2023

All Annual Results

Company CV

About Genprex, Inc.

Genprex, Inc.

Pharmaceuticals & Biotechnology

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).

Company Coordinates

Company Details

1601 Trinity St Bldg B , AUSTIN TX : 78712-1765

Tel: 1 512 5377997

https://www.genprex.com/

Registrar Details

Genprex, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Genprex, Inc.?

Watch in Real-Time

What does Genprex, Inc. do?

Who are in the management team of Genprex, Inc.?

Is Genprex, Inc. technically bullish or bearish?

Compare Genprex, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Genprex, Inc.

Company Coordinates